Status:

UNKNOWN

Accessory Pathway Antegrade Effective Refractory Period Among WPW Patients: the Risk in Relation to the Location

Lead Sponsor:

Assiut University

Conditions:

Wolff-Parkinson-White Syndrome

Eligibility:

All Genders

Brief Summary

To correlate the antegrade effective refractory period of the accessory pathway with its anatomical location in the heart. To investigate whether the accessory pathway location can predict the high r...

Detailed Description

The Wolf-Parkinson-White (WPW) syndrome is a clinical entity characterized by the presence of ≥1 accessory pathways between the atria and the ventricles pre-disposing patients to arrhythmias. Anterogr...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • all patients with WPW admitted to Assuit university hospital and subjected to invasive EPS
  • Exclusion criteria:
  • heart failure
  • cardiomyopathy

Exclusion

    Key Trial Info

    Start Date :

    March 1 2020

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2023

    Estimated Enrollment :

    35 Patients enrolled

    Trial Details

    Trial ID

    NCT04106622

    Start Date

    March 1 2020

    End Date

    March 1 2023

    Last Update

    January 30 2020

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Accessory Pathway Antegrade Effective Refractory Period Among WPW Patients: the Risk in Relation to the Location | DecenTrialz